# Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

> **NCT00967512** · PHASE2 · WITHDRAWN · sponsor: **Eleos, Inc.**

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** cenersen
- **DRUG:** placebo
- **DRUG:** idarubicin, cytarabine

## Key facts

- **NCT ID:** NCT00967512
- **Lead sponsor:** Eleos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Was Terminated due to lack of Funding.
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967512, "Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00967512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*